Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott A Hubers

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Circulation|July 21, 2016
Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition"Scott A Hubers, Nancy J Brown
Circulation|March 16, 2016
Combined Angiotensin Receptor Antagonism and Neprilysin InhibitionScott A Hubers, Nancy J Brown
Mayo Clinic Proceedings|April 18, 2020
Infective Endocarditis: A Contemporary ReviewScott A Hubers, Daniel C DeSimone, Bernard J Gersh, et al.
Circulation. Heart Failure|November 8, 2024
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical TrialScott A Hubers, Sherry L Benike, Bradley K Johnson, et al.
Heart (British Cardiac Society)|August 5, 2020
B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trialScott A Hubers, John A Schirger, S Jeson Sangaralingham, et al.
The Journal of Allergy and Clinical Immunology|July 24, 2018
Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedemaScott A Hubers, Kevin Kohm, Shouzuo Wei, et al.
Journal of the American Heart Association|January 10, 2022
Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart FailureScott A Hubers, Siu-Hin Wan, Fadi W Adel, et al.
Analytical Chemistry|December 3, 2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MSCéline Vocat, Marielle Dunand, Scott A Hubers, et al.
Journal of the Endocrine Society|September 19, 2019
Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS InhibitionJessica R Wilson, Scott Jafarian Kerman, Scott A Hubers, et al.
Hypertension (Dallas, Tex. : 1979)|January 20, 2022
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor TreatmentJessica R Wilson, Erica M Garner, Mona Mashayekhi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Circulation|July 21, 2016
Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition"Scott A Hubers, Nancy J Brown
Circulation|March 16, 2016
Combined Angiotensin Receptor Antagonism and Neprilysin InhibitionScott A Hubers, Nancy J Brown
Mayo Clinic Proceedings|April 18, 2020
Infective Endocarditis: A Contemporary ReviewScott A Hubers, Daniel C DeSimone, Bernard J Gersh, et al.
Circulation. Heart Failure|November 8, 2024
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical TrialScott A Hubers, Sherry L Benike, Bradley K Johnson, et al.
Heart (British Cardiac Society)|August 5, 2020
B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trialScott A Hubers, John A Schirger, S Jeson Sangaralingham, et al.
The Journal of Allergy and Clinical Immunology|July 24, 2018
Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedemaScott A Hubers, Kevin Kohm, Shouzuo Wei, et al.
Journal of the American Heart Association|January 10, 2022
Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart FailureScott A Hubers, Siu-Hin Wan, Fadi W Adel, et al.
Analytical Chemistry|December 3, 2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MSCéline Vocat, Marielle Dunand, Scott A Hubers, et al.
Journal of the Endocrine Society|September 19, 2019
Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS InhibitionJessica R Wilson, Scott Jafarian Kerman, Scott A Hubers, et al.
Hypertension (Dallas, Tex. : 1979)|January 20, 2022
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor TreatmentJessica R Wilson, Erica M Garner, Mona Mashayekhi, et al.
Pageof 2